The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Caramelo, Belen
Munoz Unceta, Nerea
Freire, Javier
Varela, Ignacio
Martin, David
Del Carmen, Sofia
Azueta, Ainara
Diaz, Pilar
Garcia-Berbel, Pilar
Sagastibelza Marinelarena, Naiara
Rey-Cardenas, Macarena
Castellano, Daniel
Climent, Miguel Angel
Puente, Javier
Irure, Juan
Revuelta, Laura
Genre, Fernanda
Cacho, Diego
Gomez, Javier
Duran, Ignacio
机构：
[1] IDIVAL, Inst Invest Valdecilla, Santander, Cantabria, Spain
[2] Hosp Univ Marques de Valdecilla, Santander, Cantabria, Spain
[3] IBBTEC, Inst Biomed & Biotecnol Cantabria, Santander, Cantabria, Spain
[4] Hosp Donostia, San Sebastian, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
[6] Hosp Univ 12 Octubre, Serv Oncol Med, Madrid, Spain
[7] Inst Valenciano Oncol, Valencia, Spain
[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain
[9] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Cantabria, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-11076; 261-566-9718-9794; 298-4768-3691-2722-5055; 283-2494; 283-183-138-12268; 298-4768-12362; 261-492-5651-9270-5657; 6; 5; 3; 2; 38092-27449; 38092-25821; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
    Yao, Ji-Ming
    Zhong, Jia-Lei
    Zhou, Qiang
    Guo, Ju
    WORLD JOURNAL OF UROLOGY, 2025, 43 (01)
  • [32] Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting
    Hobeika, Charbel
    Dawsey, Scott
    Patgunarajah, Ubenthira
    Lynn, David
    Pramod, Nikhil
    Wei, Wei
    Nair, Monica
    Maroli, Kimberly
    Martin, Allison
    Ornstein, Moshe Chaim
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Nizam, Amanda
    Bonham, Amanda
    Mian, Omar Y.
    Pavicic, Paul G.
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 640 - 640
  • [33] Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
    Morales Barrera, R.
    Matos, I.
    Gonzalez, M.
    Suarez, C.
    Ros, J.
    Valverde, C.
    Fernandez, C.
    Hierro, C.
    Serra, E.
    Mateo, J.
    Gutierrez, S.
    Martin Liberal, J.
    Quintana, A.
    Dienstmann, R.
    Serrano, C.
    Garralda, E.
    Carles, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 369 - +
  • [34] Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting
    Lynn, David
    Hobeika, Charbel
    Patgunarajah, Ubenthira
    Dawsey, Scott
    Pramod, Nikhil
    Wei, Wei
    Nair, Monica
    Maroli, Kimberly
    Martin, Allison
    Ornstein, Moshe Chaim
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Nizam, Amanda
    Bonham, Amanda
    Mian, Omar Y.
    Pavicic, Paul G.
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 571 - 571
  • [35] Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Alice Tzeng
    C. Marcela Diaz-Montero
    Patricia A. Rayman
    Jin S. Kim
    Paul G. Pavicic
    James H. Finke
    Pedro C. Barata
    Marcelo Lamenza
    Sarah Devonshire
    Kim Schach
    Hamid Emamekhoo
    Marc S. Ernstoff
    Christopher J. Hoimes
    Brian I. Rini
    Jorge A. Garcia
    Timothy D. Gilligan
    Moshe C. Ornstein
    Petros Grivas
    Targeted Oncology, 2018, 13 : 599 - 609
  • [36] FOXP3+T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
    Adib, Elio
    El Zarif, Talal
    Freeman, Dory
    Labban, Muhieddine
    Curran, Catherine
    Sharma, Bijaya
    Song, Jane
    Felt, Kristen
    Nassar, Amin
    Davidsohn, Matthew
    Rodig, Scott J.
    Choueiri, Toni K.
    Kwiatkowski, David J.
    Ravi, Praful
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin S.
    Pavicic, Paul G., Jr.
    Finke, James H.
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe C.
    Grivas, Petros
    TARGETED ONCOLOGY, 2018, 13 (05) : 599 - 609
  • [38] Molecular analysis of urothelial carcinoma to predict the efficacy of immune checkpoint inhibitor therapy
    Varadi, M.
    Horvath, O.
    Fazekas, T.
    Csizmarik, A.
    Modos, O.
    Szeles, A.
    Kenessey, I
    Reis, H.
    Olah, C.
    Hadaschik, B.
    Krafft, U.
    Ting, S.
    Furka, A.
    Nyirady, P.
    Szarvas, T.
    EUROPEAN UROLOGY, 2023, 83
  • [39] Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
    Ji, Jun Ho
    Ha, Sang Yun
    Lee, Danbi
    Sankar, Kamya
    Koltsova, Ekaterina K.
    Abou-Alfa, Ghassan K.
    Yang, Ju Dong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [40] Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma
    Beck, W.
    Rose, T. L.
    Milowsky, M., I
    Vincent, B. G.
    Klomp, J.
    Kim, W. Y.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 906 - 906
12345